ChiCTR-TRC-09000496
结束
/
/
/
2009-08-11
/
/
冠状动脉粥样硬化性心脏病
血流储备分数（FFR）指导双支架术治疗冠脉真性分叉病变的临床意义（DK-CRUSH IV）
双支架术治疗冠脉真性分叉病变后冠脉血流生理性改变的临床意义
210006
真性分叉病变是当今冠脉介入领域的一大挑战，单支架或双支架术孰优孰劣尚无定论，但为了同时保护主支和边支，首先考虑使用双支架术；本研究旨在FFR指导下使用不同的双支架术式（DK CRUSH和step "T"技术）处理冠脉真性分叉病变有效性的对照研究。
随机平行对照
Ⅰ期
随机数字表
患者 是
自筹
/
100
/
2009-09-01
2012-09-30
/
1. Age 18 to 75 years old; 2. Able and willing to provide signed informed consent; 3. Left ventricular ejection fraction >30%; 4. True bifurcation lesion (medina classification 1, 1, 1 or 1, 0, 1 or 0, 1, 1) with diameter of MB by visual estimate>=2.5mm and diameter of SB by visual estimate>=2.5mm and without other lesions in whole coronary tree 5. Lesions in main vessel could be completely covered by 2 stents; 6. Patients with NSTEAMI, CTO or distal left main disease were also eligible.；
登录查看1. Life expectancy<1 year; 2. Women in pregnancy; 3. Severe diffuse, calicified lesions; 4. Left ventricular ejection fraction<30%; 5. Plasma platelet count<10*10^9/L; 6. S-creatinine>3mg/dL; 7. Cerebrovascular events within 6 months; 8. Allergy to of the drugs used (aspirin, clopidogrel, sirolimus); 9. STEAMI or other phenomenon with refractory low blood pressure or can not tolerate adenosin.；
登录查看南京市第一医院
210006
约印创投2025-01-16
求实药社2025-01-16
Genhouse2025-01-16
IPHASE2025-01-16
动脉网2025-01-16
动脉网-最新2025-01-16
药明康德2025-01-16
药明康德2025-01-16
再鼎医药2025-01-16
Rimonci2025-01-15
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
